Newly Approved Insomnia Drug Bests Zolpidem in Phase 3 Newly Approved Insomnia Drug Bests Zolpidem in Phase 3

In a case of unusual timing, the FDA approved lemborexant to treat insomnia the same week that investigators published phase 3 safety and efficacy findings.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news